Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Biopharmaceutical company Immunic, Inc. announced that it has been granted a key European patent, which will provide important protection for the administration regimen related to Vidofludimus calcium.

Biopharmaceutical company Immunic, Inc. announced that it has been granted a key European patent, which will provide important protection for the administration regimen related to Vidofludimus calcium.

老虎证券老虎证券2026/03/10 10:42
Show original
The granting of this patent further consolidates the company's intellectual property position in the development of this innovative therapy.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!